利用临床基因组数据库分析非小细胞肺癌患者特征与肿瘤基因组学同临床结局的关联
本研究将275家美国肿瘤诊疗机构的电子健康记录临床数据与全面基因组图谱结果链接,纳入28998例患者,其中4064例非小细胞肺癌患者纳入探索性分析。结果显示,携带驱动基因改变的患者接受靶向治疗较未接受者总生存改善,肿瘤突变负荷与吸烟状态及EGFR、ALK、RET、ROS1改变相关,在接受抗PD-1/PD-L1治疗的患者中肿瘤突变负荷≥20与总生存、治疗时间和临床获益率改善相关。
要点
- 携带驱动基因改变的非小细胞肺癌患者接受靶向治疗较未接受者总生存改善。
- 吸烟者肿瘤突变负荷高于不吸烟者,EGFR、ALK、RET、ROS1改变者肿瘤突变负荷较低。
- 接受抗PD-1/PD-L1治疗且肿瘤突变负荷≥20的患者总生存和临床获益率改善。
核心结论
- 在链接全面基因组图谱结果的纵向临床数据库的非小细胞肺癌患者中,探索性分析重复了既往描述的临床与基因组特征之间、驱动突变与靶向治疗反应之间以及肿瘤突变负荷与免疫治疗反应之间的关联。
- 这些发现证明从常规临床经验创建临床基因组数据库的可行性,并为在肿瘤学中评估该方法的进一步研究和发现提供支持。
研究设计与样本
- 将来自电子健康记录的临床数据与275家美国肿瘤诊疗机构的28998例患者的全面基因组图谱结果链接。
- 在4064例非小细胞肺癌患者中开展肿瘤基因组学与患者特征同临床结局之间的探索性关联分析,数据获取时间为2011年1月1日至2018年1月1日。
主要发现
- 4064例非小细胞肺癌患者中位年龄66.0岁,女性占51.9%,3183例(78.3%)有吸烟史,3153例(77.6%)为非鳞癌,871例(21.4%)存在EGFR、ALK或ROS1改变(EGFR 701例[17.2%]、ALK 128例[3.1%]、ROS1 42例[1.0%]),7年内死亡1946例。
- 携带驱动基因改变的患者中,接受靶向治疗者(n=575)较未接受者(n=560)自晚期诊断起总生存改善,中位总生存分别为18.6个月(95%CI 15.2-21.7)与11.4个月(95%CI 9.7-12.5),P<.001。
- 吸烟者肿瘤突变负荷(突变/Mb)显著高于不吸烟者(8.7 [IQR 4.4-14.8] vs 2.6 [IQR 1.7-5.2],P<.001);EGFR改变者较无改变者显著降低(3.5 [IQR 1.76-6.1] vs 7.8 [IQR 3.5-13.9],P<.001),ALK改变者较无改变者显著降低(2.1 [IQR 0.9-4.0] vs 7.0 [IQR 3.5-13.0],P<.001),RET改变者较无改变者显著降低(4.6 [IQR 1.7-8.7] vs 7.0 [IQR 2.6-13.0],P=.004),ROS1改变者较无改变者显著降低(4.0 [IQR 1.2-9.6] vs 7.0 [IQR 2.6-13.0],P=.03)。
- 接受抗PD-1/PD-L1治疗的患者(n=1290,31.7%)中,肿瘤突变负荷≥20较<20与自治疗开始总生存改善相关(16.8个月 [95%CI 11.6-24.9] vs 8.5个月 [95%CI 7.6-9.7],P<.001),治疗时间延长(7.8个月 [95%CI 5.5-11.1] vs 3.3个月 [95%CI 2.8-3.7],P<.001),临床获益率增加(80.7% vs 56.7%,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine. OBJECTIVE: To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: Clinical data from EHRs were linked with CGP results for 28 998 patients from 275 US oncology practices. Among 4064 patients with NSCLC, exploratory associations between tumor genomics and patient characteristics with clinical outcomes were conducted, with data obtained between January 1, 2011, and January 1, 2018. EXPOSURES: Tumor CGP, including presence of a driver alteration (a pathogenic or likely pathogenic alteration in a gene shown to drive tumor growth); tumor mutation burden (TMB), defined as the number of mutations per megabase; and clinical characteristics gathered from EHRs. MAIN OUTCOMES AND MEASURES: Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy. RESULTS: Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0%] with ROS1 alterations). There were 1946 deaths in 7 years. For patients with a driver alteration, improved OS was observed among those treated with (n = 575) vs not treated with (n = 560) targeted therapies (median, 18.6 months [95% CI, 15.2-21.7] vs 11.4 months [95% CI, 9.7-12.5] from advanced diagnosis; P < .001). TMB (in mutations/Mb) was significantly higher among smokers vs nonsmokers (8.7 [IQR, 4.4-14.8] vs 2.6 [IQR, 1.7-5.2]; P < .001) and significantly lower among patients with vs without an alteration in EGFR (3.5 [IQR, 1.76-6.1] vs 7.8 [IQR, 3.5-13.9]; P < .001), ALK (2.1 [IQR, 0.9-4.0] vs 7.0 [IQR, 3.5-13.0]; P < .001), RET (4.6 [IQR, 1.7-8.7] vs 7.0 [IQR, 2.6-13.0]; P = .004), or ROS1 (4.0 [IQR, 1.2-9.6] vs 7.0 [IQR, 2.6-13.0]; P = .03). In patients treated with anti-PD-1/PD-L1 therapies (n = 1290, 31.7%), TMB of 20 or more was significantly associated with improved OS from therapy initiation (16.8 months [95% CI, 11.6-24.9] vs 8.5 months [95% CI, 7.6-9.7]; P < .001), longer time receiving therapy (7.8 months [95% CI, 5.5-11.1] vs 3.3 months [95% CI, 2.8-3.7]; P < .001), and increased clinical benefit rate (80.7% vs 56.7%; P < .001) vs TMB less than 20. CONCLUSIONS AND RELEVANCE: Among patients with NSCLC included in a longitudinal database of clinical data linked to CGP results from routine care, exploratory analyses replicated previously described associations between clinical and genomic characteristics, between driver mutations and response to targeted therapy, and between TMB and response to immunotherapy. These findings demonstrate the feasibility of creating a clinicogenomic database derived from routine clinical experience and provide support for further research and discovery evaluating this approach in oncology.
引用
- Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. 2019. PMID: 30964529. doi:10.1001/jama.2019.3241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。